Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Thakkar, Jesus Gonzalez-Lugo, Niyati Goradia, Radhika Gali, L. Shapiro, K. Pradhan, Shafia Rahman, So Kim, B. Ko, R. Sica, N. Kornblum, Lizamarie Bachier-Rodriguez, Margaret McCort, S. Goel, R. Perez-soler, S. Packer, J. Sparano, B. Gartrell, D. Makower, Yitz Goldstein, L. Wolgast, Amit Verma, B. Halmos (2021)
Seroconversion rates following COVID-19 vaccination among patients with cancerCancer Cell, 39
R. Libster, Gonzalo Marc, Diego Wappner, Silvina Coviello, Alejandra Bianchi, V. Braem, I. Esteban, M. Caballero, C. Wood, M. Berrueta, Aníbal Rondan, G. Lescano, Pablo Cruz, Yvonne Ritou, V. Viña, D. Paggi, S. Esperante, Adrián Ferreti, G. Ofman, Álvaro Ciganda, Rocio Rodriguez, J. Lantos, R. Valentini, Nicolás Itcovici, A. Hintze, M. Oyarvide, Candela Etchegaray, Alejandra Neira, Ivonne Name, Julieta Alfonso, R. Castelo, G. Caruso, Sofía Rapelius, F. Alvez, F. Etchenique, F. Dimase, D. Álvarez, S. Aranda, C. Yanotti, Julián Luca, Sofía Baglivo, S. Laudanno, Florencia Nowogrodzki, R. Larrea, M. Silveyra, Gabriel Leberzstein, Alejandra Debonis, J. Molinos, M. González, E. Perez, Nicolás Kreplak, Susana Argüello, L. Gibbons, F. Althabe, E. Bergel, F. Polack (2021)
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older AdultsThe New England Journal of Medicine
Joshua Hill, C. Ujjani, A. Greninger, M. Shadman, A. Gopal (2021)
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patientCancer Cell, 39
A. Addeo, Pankil Shah, N. Bordry, R. Hudson, Brenna Albracht, M. Marco, V. Kaklamani, P. Dietrich, B. Taylor, Pierre Simand, Darpan Patel, Jing Wang, I. Labidi-Galy, S. Fertani, R. Leach, Jose Sandoval, R. Mesa, K. Lathrop, N. Mach, D. Shah (2021)
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancerCancer Cell, 39
(2021)
Analysesofrisk,racialdisparity,andoutcomes among US patients with cancer and COVID-19 infection
Y. Herishanu, I. Avivi, A. Aharon, G. Shefer, S. Levi, Yotam Bronstein, M. Morales, T. Ziv, Yamit Arbel, L. Scarfò, E. Joffe, C. Perry, P. Ghia (2021)
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaBlood, 137
(2021)
Efficacyof theBNT162b2mRNACOVID19 vaccine in patients with chronic lymphocytic leukemia
Lennard Lee, J. Cazier, T. Starkey, S. Briggs, R. Arnold, Vartika Bisht, S. Booth, N. Campton, V. Cheng, G. Collins, H. Curley, Philip Earwaker, M. Fittall, S. Gennatas, A. Goel, Simon Hartley, D. Hughes, D. Kerr, Alvin Lee, R. Lee, S. Lee, H. McKenzie, Christopher Middleton, N. Murugaesu, T. Newsom-Davis, A. Olsson-Brown, C. Palles, T. Powles, E. Protheroe, K. Purshouse, A. Sharma-Oates, S. Sivakumar, Ashley Smith, Oliver Topping, C. Turnbull, C. Várnai, A. Briggs, G. Middleton, R. Kerr, A. Gault, Michael Agnieszka, A. Bedair, A. Ghaus, A. Akingboye, A. Maynard, Alexander Pawsey, A. Mohamed, A. Okines, A. Massey, A. Kwan, Ana Ferreira, A. Angelakas, A. Wu, A. Tivey, A. Armstrong, A. Madhan, A. Pillai, A. Poon-King, B. Kurec, C. Usborne, C. Dobeson, C. Thirlwell, C. Mitchell, C. Sng, C. Scrase, C. Jingree, Clair Brunner, Claire Fuller, C. Griffin, C. Barrington, D. Muller, D. Ottaviani, D. Gilbert, Eliana Tacconi, E. Copson, E. Renninson, E. Cattell, Emma Burke, F. Smith, Francesca Holt, G. Soosaipillai, H. Boyce, H. Shaw, Helen Hollis, H. Bowyer, I. Anil, J. Illingworth, J. Gibson, J. Bhosle, J. Best, Jane Barrett, J. Noble, J. Sacco, J. Chacko, J. Chackathayil, K. Banfill, L. Feeney, L. Horsley, L. Cammaert, L. Mukherjee, L. Eastlake, Louise Devereaux, L. Melcher, Lucy Cook, M. Teng, M. Hewish, M. Bhattacharyya, M. Choudhury, M. Baxter, M. Scott-Brown, M. Fittall, M. Tilby, M. Rowe, Mohammed Alihilali, M. Galazi, N. Yousaf, N. Chopra, N. Cox, O. Chan, O. Sheikh, P. Ramage, P. Greaves, P. Leonard, P. Hall, Piangfan Naksukpaiboon, P. Corrie, R. Peck, R. Sharkey, R. Bolton, R. Sargent, R. Jyothirmayi, R. Goldstein, R. Oakes, R. Shotton, R. Kanani, R. Board, R. Pettengell, R. Claydon, S. Moody, S. Massalha, S. Kathirgamakarthigeyan, S. Dolly, S. Derby, S. Lowndes, S. Benafif, Sarah Eeckelaers, S. Kingdon, S. Ayers, Sean Brown, S. Ellis, S. Parikh, S. Pugh, S. Shamas, S. Wyatt, S. Grumett, S. Lau, Y. Wong, S. McGrath, S. Cornthwaite, S. Hibbs, Tania Tillet, Taslima Rabbi, T. Robinson, T. Roques, V. Angelis, V. Woodcock, V. Brown, Ying Peng, Y. Drew, Z. Hudson (2020)
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyThe Lancet. Oncology, 21
Barrière Jérôme, Chamorey Emmanuel, Adjtoutah Zoubir, Castelnau Olivier, M. Abakar, Marco Sabine, Petit Emmanuel, Leysalle Axel, Raimondi Vincent, Carles Michel (2021)
Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumorsAnnals of Oncology, 32
(2021)
ImmunogenicityoftheBNT 162 b 2 COVID - 19 mRNA vaccine and early clinical outcomes in patients with haematologicalmalignancies in Lithuania : a national prospective cohort study
T. Goshen-Lago, I. Waldhorn, Roy Holland, Moran Szwarcwort-Cohen, A. Reiner-Benaim, Y. Shachor-Meyouhas, K. Hussein, Liana Fahoum, Mali Baruch, A. Peer, Y. Reiter, R. Almog, M. Halberthal, I. Ben-Aharon (2021)
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for CancerJAMA Oncology, 7
Anonymous (2021)
Cancer Research in 2021Cancer Cell, 39
N. Doria-Rose, M. Suthar, M. Makowski, S. O'connell, A. McDermott, B. Flach, J. Ledgerwood, J. Mascola, B. Graham, Bob Lin, S. O'dell, S. Schmidt, A. Widge, V. Edara, E. Anderson, L. Lai, K. Floyd, N. Rouphael, V. Zarnitsyna, P. Roberts, M. Makhene, Wendy Buchanan, C. Luke, J. Beigel, L. Jackson, K. Neuzil, H. Bennett, B. Leav, J. Albert, Pratap Kunwar (2021)
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19The New England Journal of Medicine, 384
V. Avanzato, V. Avanzato, M. Matson, M. Matson, Stephanie Seifert, R. Pryce, Brandi Williamson, S. Anzick, Kent Barbian, Seth Judson, Elizabeth Fischer, C. Martens, Thomas Bowden, E. Wit, Francis Riedo, V. Munster (2020)
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with CancerCell, 183
W. Liang, W. Guan, Ruchong Chen, Wei Wang, Jianfu Li, Ke Xu, Caichen Li, Qing Ai, Weixiang Lu, Hengrui Liang, Shiyue Li, Jianxing He (2020)
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet. Oncology, 21
A. Pollard, E. Bijker (2020)
A guide to vaccinology: from basic principles to new developmentsNature Reviews. Immunology, 21
L. Monin, Adam Laing, M. Muñoz-Ruiz, Duncan McKenzie, Irene Barrio, Thanussuyah Alaguthurai, C. Domingo-Vila, T. Hayday, C. Graham, J. Seow, Sultan Abdul-Jawad, Shraddha Kamdar, E. Harvey-Jones, R. Graham, J. Cooper, Muhammad Khan, Jennifer Vidler, Helen Kakkassery, Shubhankar Sinha, Richard Davis, L. Dupont, I. Quijorna, Charlotte O’Brien-Gore, Puay Lee, J. Eum, M. Poole, Magdalene Joseph, Daniel Davies, Yin Wu, A. Swampillai, B. North, A. Montes, M. Harries, A. Rigg, J. Spicer, M. Malim, P. Fields, P. Patten, F. Rosa, S. Papa, T. Tree, K. Doores, A. Hayday, S. Irshad (2021)
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyThe Lancet. Oncology, 22
Amir Massarweh, N. Eliakim‐Raz, A. Stemmer, A. Levy-Barda, S. Yust-Katz, A. Zer, A. Benouaich‐Amiel, H. Ben‐Zvi, N. Moskovits, B. Brenner, J. Bishara, D. Yahav, B. Tadmor, T. Zaks, S. Stemmer (2021)
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for CancerJAMA Oncology, 7
A. Desai, Rohit Gupta, S. Advani, L. Ouellette, N. Kuderer, G. Lyman, Ang Li (2020)
Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta‐analysis of cohort studiesCancer, 127
W. Chia, Feng Zhu, S. Ong, B. Young, Siew‐Wai Fong, N. Bert, C. Tan, Charles Tiu, Jinyan Zhang, S. Tan, S. Pada, Y. Chan, C. Tham, Kamini Kunasegaran, M. Chen, J. Low, Y. Leo, L. Rénia, A. Bertoletti, L. Ng, D. Lye, Lin‐Fa Wang (2021)
Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal studyThe Lancet. Microbe, 2
W. Carman, A. Elder, L. Wallace, K. McAulay, A. Walker, G. Murray, D. Stott (2000)
Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trialThe Lancet, 355
(2006)
Effectiveness of an influenza vaccine programmeforcarehomestaff topreventdeath,morbidity, andhealthserviceuseamongresidents: clusterrandomised controlledtrial. BMJ
K. Maneikis, K. Šablauskas, Ugne Ringeleviciute, V. Vaitekenaite, R. Čekauskienė, L. Kryžauskaitė, Daniel Naumovas, V. Banys, V. Pečeliūnas, T. Beinortas, L. Griškevičius (2021)
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort studyThe Lancet. Haematology, 8
A. Hayward, R. Harling, S. Wetten, Anne Johnson, S. Munro, J. Smedley, S. Murad, J. Watson (2006)
Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trialBMJ : British Medical Journal, 333
QuanQiu Wang, N. Berger, Rong Xu (2020)
Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection.JAMA oncology
(2021)
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients withcancer: interimanalysisofaprospectiveobservational study
Sultan Abdul-Jawad, L. Bau, Thanussuyah Alaguthurai, Irene Barrio, Adam Laing, T. Hayday, L. Monin, M. Muñoz-Ruiz, L. Mcdonald, I. Quijorna, Duncan McKenzie, Richard Davis, A. Lorenc, J. Chan, Sarah Ryan, Eva Bugallo-Blanco, Rozalyn Yorke, Shraddha Kamdar, M. Fish, Iva Zlatareva, P. Vantourout, Aislinn Jennings, S. Gee, K. Doores, K. Bailey, Sophie Hazell, J. Naurois, C. Moss, B. Russell, A. Khan, M. Rowley, R. Benjamin, D. Enting, D. Alrifai, Yin Wu, You Zhou, P. Barber, T. Ng, J. Spicer, M. Hemelrijck, Mayur Kumar, Jennifer Vidler, Y. Lwin, P. Fields, S. Karagiannis, A. Coolen, A. Rigg, S. Papa, A. Hayday, P. Patten, S. Irshad (2021)
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer PatientsCancer Cell, 39
J. Jee, M. Foote, M. Lumish, Aaron Stonestrom, B. Wills, V. Narendra, Viswatej Avutu, Y. Murciano-Goroff, Jason Chan, Andriy Derkach, J. Philip, Rimma Belenkaya, M. Kerpelev, M. Maloy, Adam Watson, Christopher Fong, Y. Janjigian, L. Diaz, K. Bolton, M. Pessin (2020)
Chemotherapy and COVID-19 Outcomes in Patients With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Oliver Oekelen, C. Gleason, Sarita Agte, K. Srivastava, K. Beach, Adolfo Aleman, Katerina Kappes, Radhika Firpo, R. Banu, M. Bermúdez-González, Rachel Chernet, E. Ferreri, D. Floda, A. Firpo-Betancourt, G. Kleiner, K. Russo, A. Salimbangon, M. Saksena, Amber Shin, J. Matthews, W. Mendez, L. Sominsky, L. Mulder, R. Mendu, T. Mouhieddine, Bo Wang, A. Chari, C. Cordon-Cardo, F. Krammer, S. Jagannath, V. Simon, A. Wajnberg, S. Parekh (2021)
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myelomaCancer Cell, 39
editorial memo (2021) 14:221–223 https://doi.org/10.1007/s12254-021-00741-1 SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients? Niklas Zojer Accepted: 19 July 2021 © Springer-Verlag GmbH Austria, part of Springer Nature 2021 Patients with cancer were reported to have an elevated pose cancer patients to severe COVID-19, due to ther- risk of acquiring SARS-CoV-2 (severe acquired respi- apeutically activated T-cells augmenting the virally in- ratory syndrome coronavirus 2) infection [1], possi- duced cytokine storm, but so far these concerns could bly indicating an increased susceptibility to the virus, not be substantiated. As in the general population, and have a high risk of developing severe COVID- mortality of COVID-19 in cancer patients increases 19 (coronavirus disease 2019), as well as dying from substantially with age. Currently, there are insuffi- the disease. In a large study from the US [2], hos- cient data for estimating COVID-19 risks for cancer pitalization for COVID-19 was necessary in 47.46% survivors, i.e., patients in long-term follow-up with- of oncologic patients, who had acquired the disease, out active disease or treatment, but highest risk for and an overall mortality of 14.93% was seen, while severe COVID-19 seems to affect cancer
memo - Magazine of European Medical Oncology – Springer Journals
Published: Sep 1, 2021
Keywords: oncology; medicine/public health, general
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.